Mucosolvan Inhalationslösung (Ambroxol Hydrochloride)

Ambroxol is used as a mucolytic agent to improve mucus clearance in several respiratory conditions.

• Acute bronchitis: reduces mucus viscosity, facilitating expectoration and easing cough.
• Chronic obstructive pulmonary disease (COPD): helps clear airway secretions, supporting better airflow and symptom control.
• Respiratory tract infections with thick mucus: loosens dense sputum, aiding drainage and reducing infection‑related discomfort.

• Ambroxol stimulates serous cells in the respiratory epithelium, increasing the production of thin, surfactant‑rich secretions. It also disrupts mucopolysaccharide fibers within mucus, lowering its viscosity. Additionally, Ambroxol may up‑regulate surfactant protein expression and increase ciliary beat frequency, further supporting mucociliary clearance. These actions collectively contribute to improved airway patency during infection or inflammation.

Ambroxol inhalation solution may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Taste alteration: transient metallic or bitter taste in the mouth.
• Cough irritation: mild increase in cough frequency during administration.
• Throat discomfort: transient soreness or irritation of the throat.
• Nausea: occasional mild nausea following inhalation.

Serious or Rare Side Effects

• Allergic reaction: rash, pruritus, angioedema, or anaphylaxis requiring immediate medical attention.
• Bronchospasm: sudden tightening of airway muscles leading to breathing difficulty.
• Severe respiratory distress: rare cases of pulmonary edema or worsening dyspnea.

When using Ambroxol inhalation solution, several precautions should be observed to ensure safety and efficacy.

• Assess respiratory status: confirm patient can tolerate inhalation without severe bronchospasm.
• Monitor for hypersensitivity: discontinue if rash, itching or swelling occurs.
• Use with caution in asthma: may provoke bronchial irritation; observe lung function.
• Avoid concurrent use of other mucolytics without medical advice.
• Store at below 25°C: keep in original container, protect from moisture and light.

Ambroxol may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Anticholinergic agents: may reduce mucociliary clearance, diminishing Ambroxol benefit.
• Strong CYP3A4 inhibitors: potential increase in systemic exposure, though inhalation limits absorption.

Moderate Interactions (Monitor Closely)

• Bronchodilators: concurrent use may enhance cough reflex; monitor respiratory response.
• Other mucolytics (e.g., N‑acetylcysteine): additive effects on mucus; assess for excessive thinning.
• Oral anticoagulants: rare reports of altered bleeding risk; observe coagulation parameters.